Skip to main content
SpringerLink
Log in

« Nouvelles » molécules anti-infectieuses. Quelle place en médecine intensive/réanimation pour l’isavuconazole ?

“New” drugs for infectious diseases: Can isavuconazole be used in intensive care?

  • Mise au Point / Update
  • Published:
Médecine Intensive Réanimation

Résumé

Ces dernières années ont été marquées dans le domaine du traitement antifongique par l’arrivée de triazolés de nouvelle génération, qui ont pris une place de premier ordre dans la prise en charge des infections fongiques filamenteuses sévères. Cependant, leurs effets secondaires et les contraintes d’administration peuvent parfois être un handicap dans leur utilisation. Dans ce contexte, la mise sur le marché en France de l’isavuconazole permet d’envisager une nouvelle alternative à l’amphotéricine B pour la prise en charge de ces infections. Nous présenterons dans cette revue les caractéristiques globales de cette molécule.

Abstract

In recent years, antifungal strategy has been modified by the new generation of triazoles, which have become drugs of first choice for the management of mould infections. However, their side effects and the constraints in using them can impair their prescription. In this context, the marketing of isavuconazole provides a new alternative to the use of amphotericin to treat these infections. We present, in this article, the main characteristics of this drug.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Références

  1. Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Nguyen MH, Segal BH, Steinbach WJ, Stevens DA, Walsh TJ, Wingard JR, Young JA, Bennett JE, (2016) Practice guidelines for the diagnosis and management of Aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 63: e1–e60

    Article  PubMed  Google Scholar 

  2. Lass-Florl C, (2011) Triazole antifungal agents in invasive fungal infections: a comparative review. Drugs 71: 2405–2419

    Article  PubMed  Google Scholar 

  3. Shirley M, Scott LJ, (2016) Isavuconazole: a review in invasive Aspergillosis and Mucormycosis. Drugs 76: 1647–1657

    Article  CAS  PubMed  Google Scholar 

  4. Nett JE, Andes DR, (2012) Antifungals: properties and clinical use. In: Calderone RA, Clancy CJ (eds) Candida and candidiasis. ASM Press, Washington, DC, pp 345–371

    Chapter  Google Scholar 

  5. Miceli MH, Kauffman CA, (2015) Isavuconazole: a new broadspectrum triazole antifungal agent. Clin Infect Dis 61: 1558–1565

    Article  CAS  PubMed  Google Scholar 

  6. Sanglard D, Odds FC, (2002) Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2: 73–85

    Article  CAS  PubMed  Google Scholar 

  7. Pfaller MA, Messer SA, Rhomberg PR, Jones RN, Castanheira M, (2013) In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds. J Clin Microbiol 51: 2608–2616

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Castanheira M, Messer SA, Rhomberg PR, Dietrich RR, Jones RN, Pfaller MA, (2014) Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values. Mycopathologia 178: 1–9

    Article  CAS  PubMed  Google Scholar 

  9. Thompson GR 3rd, Wiederhold NP, Fothergill AW, Vallor AC, Wickes BL, Patterson TF, (2009) Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. Antimicrob Agents Chemother 53: 309–311

    Article  CAS  PubMed  Google Scholar 

  10. Thompson GR 3rd, Wiederhold NP, Sutton DA, Fothergill A, Patterson TF, (2009) In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species. J Antimicrob Chemother 64: 79–83

    Article  CAS  PubMed  Google Scholar 

  11. Warn PA, Sharp A, Denning DW, (2006) In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp. J Antimicrob Chemother 57: 135–138

    Article  CAS  PubMed  Google Scholar 

  12. Espinel-Ingroff A, Chowdhary A, Gonzalez GM, Lass-Florl C, Martin-Mazuelos E, Meis J, Pelaez T, Pfaller MA, Turnidge J, (2013) Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI M38-A2 broth microdilution method. Antimicrob Agents Chemother 57: 3823–3828

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Chowdhary A, Kathuria S, Randhawa HS, Gaur SN, Klaassen CH, Meis JF, (2012) Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the Cyp51A gene in India. J Antimicrob Chemother 67: 362–366

    Article  CAS  PubMed  Google Scholar 

  14. Camps SM, van der Linden JW, Li Y, Kuijper EJ, van Dissel JT, Verweij PE, Melchers WJ, (2012) Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature. Antimicrob Agents Chemother 56: 10–16

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Verweij PE, Gonzalez GM, Wiedrhold NP, Lass-Florl C, Warn P, Heep M, Ghannoum MA, Guinea J, (2009) In vitro antifungal activity of isavuconazole against 345 Mucorales isolates collected at study centers in eight countries. J Chemother 21: 272–281

    Article  CAS  PubMed  Google Scholar 

  16. Schmitt-Hoffmann A, Roos B, Heep M, Schleimer M, Weidekamm E, Brown T, Roehrle M, Beglinger C, (2006) Singleascending-dose pharmacokinetics and safety of the novel broadspectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 mg) and oral administrations (100, 200, and 400 mg) of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother 50: 279–285

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Schmitt-Hoffmann A, Roos B, Maares J, Heep M, Spickerman J, Weidekamm E, Brown T, Roehrle M, (2006) Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother 50: 286–293

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Livermore J, Hope W, (2012) Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections. Expert Opin Drug Metab Toxicol 8: 759–765

    Article  CAS  PubMed  Google Scholar 

  19. Cornely OA, Bohme A, Schmitt-Hoffmann A, Ullmann AJ, (2015) Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study. Antimicrob Agents Chemother 59: 2078–2085

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Desai A, Kovanda L, Kowalski D, Lu Q, Townsend R, Bonate PL, (2016) Population pharmacokinetics of isavuconazole from phase 1 and phase 3 (SECURE) trials in adults and target attainment in patients with invasive infections due to Aspergillus and other filamentous fungi. Antimicrob Agents Chemother 60: 5483–5491

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Majithiya J, Sharp A, Parmar A, Denning DW, Warn PA, (2009) Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei. J Antimicrob Chemother 63: 161–166

    Article  CAS  PubMed  Google Scholar 

  22. Lepak AJ, Marchillo K, Van Hecker J, Diekema D, Andes DR, (2013) Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model. Antimicrob Agents Chemother 57: 5642–5648

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Lepak AJ, Marchillo K, Vanhecker J, Andes DR, (2013) Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary Aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus. Antimicrob Agents Chemother 57: 6284–6289

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Seyedmousavi S, Bruggemann RJ, Meis JF, Melchers WJ, Verweij PE, Mouton JW, (2015) Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model. Antimicrob Agents Chemother 59: 2855–2866

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Maertens JA, Raad, II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, Bow EJ, Rahav G, Neofytos D, Aoun M, Baddley JW, Giladi M, Heinz WJ, Herbrecht R, Hope W, Karthaus M, Lee DG, Lortholary O, Morrison VA, Oren I, Selleslag D, Shoham S, Thompson GR 3rd, Lee M, Maher RM, Schmitt-Hoffmann AH, Zeiher B, Ullmann AJ, (2016) Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet 387: 760–769

    Article  CAS  PubMed  Google Scholar 

  26. Horn D, Goff D, Khandelwal N, Spalding J, Azie N, Shi F, Franks B, Shorr AF, (2016) Hospital resource use of patients receiving isavuconazole vs. voriconazole for invasive mold infections in the phase III SECURE trial. J Med Econ 19: 728–734

    Article  PubMed  Google Scholar 

  27. Harrington R, Lee E, Yang H, Wei J, Messali A, Azie N, Wu EQ, Spalding J, (2017) Cost–effectiveness analysis of isavuconazole vs. voriconazole as first-line treatment for invasive Aspergillosis. Adv Ther 34: 207–220

    Article  PubMed  Google Scholar 

  28. Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson GR 3rd, Alangaden GJ, Brown JM, Fredricks DN, Heinz WJ, Herbrecht R, Klimko N, Klyasova G, Maertens JA, Melinkeri SR, Oren I, Pappas PG, Racil Z, Rahav G, Santos R, Schwartz S, Vehreschild JJ, Young JA, Chetchotisakd P, Jaruratanasirikul S, Kanj SS, Engelhardt M, Kaufhold A, Ito M, Lee M, Sasse C, Maher RM, Zeiher B, Vehreschild MJ, Vital and FungiScope Mucormycosis Investigators, (2016) Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis 16: 828–837

    Article  CAS  PubMed  Google Scholar 

  29. Thompson GR 3rd, Rendon A, Ribeiro Dos Santos R, Queiroz-Telles F, Ostrosky-Zeichner L, Azie N, Maher R, Lee M, Kovanda L, Engelhardt M, Vazquez JA, Cornely OA, Perfect JR, (2016) Isavuconazole treatment of Cryptococcosis and dimorphic mycoses. Clin Infect Dis 63: 356–362

    Article  PubMed  PubMed Central  Google Scholar 

  30. HAS, (2016). In: Editor (ed) (eds) Book., City, http://www.hassante.fr/portail/upload/docs/evamed/CT-14849_CRESEMBA_PIC_ INS_Avis2_CT14849.pdf

    Google Scholar 

  31. Tissot F, Agrawal S, Pagano L, Petrikkos G, Groll AH, Skiada A, Lass-Flörl C, Calandra T, Viscoli C, Herbrecht R, (2017) ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica 102: 433–444

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pôle de réanimation, hôpital Salengro–CHRU de Lille, rue Émile-Laine, F-59037, Lille cedex, France

    J. Poissy, T. Duburcq, C. Thieffry, E. Decrucq-Parmentier & D. Mathieu

  2. Inserm, université de Lille, CHU de Lille, U995-2 — LIRIC — Lille Inflammation Research International Center, F-59000, Lille, France

    J. Poissy

  3. F-59000, Lille, France

    J. Poissy, T. Duburcq, C. Thieffry, E. Decrucq-Parmentier & D. Mathieu

Authors
  1. J. Poissy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Duburcq
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Thieffry
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. Decrucq-Parmentier
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D. Mathieu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Poissy.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Poissy, J., Duburcq, T., Thieffry, C. et al. « Nouvelles » molécules anti-infectieuses. Quelle place en médecine intensive/réanimation pour l’isavuconazole ?. Méd. Intensive Réa 26, 218–223 (2017). https://doi.org/10.1007/s13546-017-1269-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13546-017-1269-9

Mots clés

Keywords

Search

Navigation